Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Auto stocks gear market ahead
Wed, 24 Nov 11:30 am

After starting today's session on a positive note Indian indices have managed to hold on to the gains. However, other key Asian markets are trading mixed. Currently, heavyweights in the Sensex are trading strong with stocks from auto and consumer durables space leading the gains. However, stocks from the IT space are trading flat.

Currently, the BSE-Sensex is trading up by around 132 points, while the NSE-Nifty is up by about 31 points. There has been some buying interest amongst the mid and small cap stocks as well with the BSE-Midcap and BSE-Smallcap indices trading higher by 1.0% and 1.5% respectively. The rupee is trading at 45.62 to the US dollar.

Pharma stocks are trading strong with Natco Pharma and Wockhardt leading the gains. However, IPCAlabs is trading in the red. As per a leading news daily, Dr Reddy's plans to take over GlaxoSmithKLine's oral penicillin business in the US. As a part of the deal Dr Reddy's will also get right to market the penicillin medicines Augmentin and Amoxil in the US. The deal is expected to close in the first half of CY11. However, the financial terms are yet to be disclosed. It may be noted that both the drugs Augmentin and Amoxil are subject to generic competition and consequently generate only minor sales for Glaxo. Thus, the disposal would allow Glaxo to focus on the newer products while it will give Dr Reddy's an entry into the US penicillin-containing antibacterial market. It will also allow Dr Reddy's to scale up its generic business in North America.

Power stocks are trading firm led by Torrent Power and GVK Power & Infra. As per a leading financial daily, Tata Power plans to invest Rs 8.5 bn till FY12 to beef up its generation, transmission and distribution capabilities. Of this Rs 6 bn will be spent on transmission and distribution while the remaining amount will be spent on increasing the company's generation capabilities. The company has seen a huge influx of new customers who have switched from Reliance Infra (RInfra) to Tata Power. As per Tata Power 50,000 customers have switched from RInfra to the company in recent months. It may be noted that Tata Power is targeting a customer base of 140,000 by March 2011 from the current 85,000.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Auto stocks gear market ahead". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.